Impact of Malaria Preexposure on Antiparasite Cellular and Humoral Immune Responses after Controlled Human Malaria Infection

Joshua M. Obiero, Seif Shekalaghe, Cornelus C. Hersmsen, Maxmillian Mpina, Else M. Bijker, Meta Roestenberg, Karina Teelen, Peter F. Billingsley, B. Kim Lee Sim, Eric R. James, Claudia A. Daubenberger, Stephen L. Hoffman, Salim Abdulla, Robert W. Sauerwein, Anja Scholzen

Radboud University Medical Center, Department of Medical Microbiology, Nijmegen, The Netherlands; Ifakara Health Institute, Bagamoyo Research and Training Center, Bagamoyo, Tanzania; Sanaria Inc., Rockville, Maryland, USA; Swiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, Basel, Switzerland; University of Basel, Basel, Switzerland

To understand the effect of previous malaria exposure on antiparasite immune responses is important for developing successful immunization strategies. Controlled human malaria infections (CHMIs) using cryopreserved Plasmodium falciparum sporozoites provide a unique opportunity to study differences in acquisition or recall of antimalarial immune responses in individuals from different transmission settings and genetic backgrounds. In this study, we compared antiparasite humoral and cellular immune responses in two cohorts of malaria-naive Dutch volunteers and Tanzanians from an area of low malarial endemicity, who were subjected to the identical CHMI protocol by intradermal injection of P. falciparum sporozoites. Samples from both trials were analyzed in parallel in a single center to ensure direct comparability of immunological outcomes. Within the Tanzanian cohort, we distinguished one group with moderate levels of preexisting antibodies to asexual P. falciparum lysate and another that, based on P. falciparum serology, resembled the malaria-naive Dutch cohort. Positive P. falciparum serology at baseline was associated with a lower parasite density at first detection by quantitative PCR (qPCR) after CHMI than that for Tanzanian volunteers with negative serology. Post-CHMI, both Tanzanian groups showed a stronger increase in anti-P. falciparum antibody titers than Dutch volunteers, indicating similar levels of B-cell memory independent of serology. In contrast to the Dutch, Tanzanians failed to increase P. falciparum-specific in vitro recall gamma interferon (IFN-γ) production after CHMI, and innate IFN-γ responses were lower in P. falciparum lysate-seropositive individuals than in seronegative individuals. In conclusion, positive P. falciparum lysate serology can be used to identify individuals with better parasite control but weaker IFN-γ responses in circulating lymphocytes, which may help to stratify volunteers in future CHMI trials in areas where malaria is endemic.

In 2012, Plasmodium falciparum malaria caused an estimated 207 million cases and 627,000 deaths, of which 90% occurred in children under 5 years of age and in pregnant women in sub-Saharan Africa (1). Major control efforts have been implemented with some success (2, 3), but malaria eradication will likely require a safe and highly protective vaccine. Subunit vaccines have thus far shown moderate efficacy at best. RTS,S is the only vaccine candidate in phase 3 trials but, despite averting substantial numbers of malaria cases (4), shows only 30 to 50% reduction in clinical disease after 12 months depending on both age and malaria endemicity and even less after 18 months (5–7). These results stress the need for more effective second-generation vaccines. Key requirements are not only the identification of novel immunogens but also a better understanding of protection-related immune responses. This includes the effect of previous malaria exposure on immune responses upon reexposure or vaccination (8, 9).

During the past 3 decades, controlled human malaria infection (CHMI) trials have become an indispensable tool not only in assessing the efficacy of candidate vaccines (10, 11) but also in evaluating immune responses induced by exposure to the malaria parasite (12–15). CHMI trials have so far been performed in countries where malaria is not endemic in previously unexposed individuals (11, 16–19). A logical next step is to study the potential differences in the acquisition, maintenance, or recall of immune responses in individuals from different transmission settings and genetic backgrounds (20, 21). The availability of aseptic, purified, cryopreserved, live P. falciparum sporozoites (PfSPZs; PfSPZ Challenge) (22) opens up opportunities to carry out CHMI trials in countries where malaria is endemic, since it bypasses the need for infecting local Anopheles mosquitoes with P. falciparum or importing P. falciparum-infected mosquitoes to the trial site. The first PfSPZ Challenge trial in malaria-naive Dutch volunteers demonstrated an infectivity rate of 83% after intradermal injections, independent of the dose given (23). Recently, PfSPZ Challenge was used for the first time during a CHMI trial in healthy adult male Tanzanians. Subunit vaccines have thus far had some success (2, 3), but malaria eradication will likely require a safe and highly protective vaccine. Subunit vaccines have thus far shown moderate efficacy at best. RTS,S is the only vaccine candidate in phase 3 trials but, despite averting substantial numbers of malaria cases (4), shows only 30 to 50% reduction in clinical disease after 12 months depending on both age and malaria endemicity and even less after 18 months (5–7). These results stress the need for more effective second-generation vaccines. Key requirements are not only the identification of novel immunogens but also a better understanding of protection-related immune responses. This includes the effect of previous malaria exposure on immune responses upon reexposure or vaccination (8, 9).


Editor: J. H. Adams
Address correspondence to Robert W. Sauerwein, robert.sauerwein@radboudumc.nl, or Anja Scholzen, anja.scholzen@radboudumc.nl.
* Present address: Joshua M. Obiero, University of California Irvine, Department of Medicine, Division of Infectious Diseases, Irvine, California, USA; Meta Roestenberg, Leiden University Medical Center, Department of Infectious Diseases, Leiden, The Netherlands.

Supplemental material for this article may be found at http://dx.doi.org/10.1128/IAI.03069-14.
Copyright © 2015, American Society for Microbiology. All Rights Reserved. doi:10.1128/IAI.03069-14
zanian volunteers, resulting in similar infection rates (24). As a follow-up, we here present results of the malaria-specific humoral and cellular immune responses in Tanzanians and Dutch volunteers who were inoculated intradermally with the same number of live PfSPZs during these CHMI studies.

MATERIALS AND METHODS

Human ethics statement. The Dutch trial (23) was approved by the Central Committee for Research Involving Human Subjects of The Netherlands (NL31885.091.10) and registered at ClinicalTrials.gov, identifier NCT 01086917. The Tanzanian trial (24) was approved by institutional review boards of the Ifakara Health Institute (IHI/IRB/No25), the National Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol.IX/1217), the Ethikkommission beider Basel (EKBB), Basel, Switzerland (EKBB 319/11), and the Tanzanian Food and Drug Administration (reference no. CE.57/180/04A/50) and registered at ClinicalTrials.gov, identifier NCT 01540903. All study teams complied with the Declaration of Helsinki and good clinical practice, including monitoring of data, and all volunteers gave written informed consent.

Clinical trial design. Samples for immunological analysis were obtained from two CHMI trials (23, 24).

The first trial, performed at Radboud University Medical Center, Nijmegen, The Netherlands, was composed of 18 healthy Dutch subjects between the ages of 19 and 30 years with no history of malaria. Any volunteer who was positive for *P. falciparum* serology or had resided in an area where malaria is endemic within the previous 6 months was excluded from the trial. Three groups (*n* = 6 per group) were infected by intradermal injections of 2,500, 10,000, or 25,000 cryopreserved PfSPZs (NF54 strain). By day 21, 15/18 volunteers had developed parasites detectable by positive blood thin smear (TS); 5/6 in each group (23). There were no differences in parasite densities at diagnosis between the three dose groups (23). For immunological analysis, nine *P. falciparum*-positive volunteers of the 10,000 (*n* = 4) and 25,000 (*n* = 5) PfSPZ dose groups were selected based on availability of plasma and peripheral blood mononuclear cells (PBMCs).

The second trial was carried out in Bagamoyo, Tanzania, with volunteers residing in Dar es Salaam (an area where malaria is hypoenemic). Twenty-four males between 20 to 35 years of age were enrolled and confirmed to be free of parasites by real-time quantitative PCR (qPCR). Subjects with a self-reported history of clinical malaria in the previous 5 years were excluded. The volunteers were divided into two groups with 12 volunteers per group and infected by intradermal injections of either 10,000 or 25,000 PfSPZs (NF54 strain). A total of 21/24 became both qPCR and blood smear positive by day 21 after infection (24). The three *P. falciparum*-negative volunteers were excluded from analysis in the present study.

PBMCs, citrate anticoagulated plasma samples from Dutch volunteers, and serum samples from Tanzanian volunteers were collected and cryopreserved 1 day before challenge (pre-CHMI) and after treatment (post-CHMI; day 35 and day 28 after infection).

DNA extraction and qPCR analysis. A total of 5 μL Zap-Oglobin II lytic reagent (Beckman Coulter) was added to 500 μL of EDTA blood, after which the samples were mixed and stored at −80°C.

DNA extraction and quantification of parasitemia by qPCR in the Dutch CHMI trial were performed in Nijmegen as described previously (25), with slight modifications. Briefly, after thawing, samples were spiked with murine white blood cells as an extraction control, and DNA was extracted with a MagnaPure LC isolation station. For detection of the extraction control and *P. falciparum* primers for the murine albumin gene and *P. falciparum* 18S rRNA were used as described previously (25). Additionally, the *P. falciparum* 18S rRNA TaqMan MGB probe AAC.AAT TGG.AGG.GCA.AG—6-carboxyfluorescein (FAM) was used.

DNA extraction and qPCR in the Tanzanian trial were carried out at the Leiden University Medical Center, Leiden, The Netherlands, as described previously (26). Phocine herpesvirus 1 (PhHV-1) was added to the isolation lysis buffer to serve as an internal control. For quantification of PhHV, the primers GGGCGAACTCAGATTGATC and GCGGTTGCCAACGTACCAAC and the probe Cy5-TTTTTTAGTGTCGCGACCATCT TGGATC were used. *P. falciparum* content in sequential samples from four CHMI volunteers.

Parasite material for immunological analysis. The *P. falciparum* NF54 strain used in both CHMI trials is the parental strain of the 3D7 clone (27). *P. falciparum* (NF54 strain) blood-stage parasites were cultured in RPMI 1640 containing 10% human A+ serum and a 3% hematocrit erythrocyte suspension in a semiautomated culture system and regularly screened for mycoplasma contamination. For *in vitro* stimulation assays, asynchronous parasites harvested at a parasitemia of approximately 10 to 20% were purified by centrifugation on a 63% Percoll density gradient to obtain mature asexual stages. This resulted in concentrations of parasitemia levels of about 80 to 90%, consisting of more than 95% schizonts/mature trophozoites. *P. falciparum*-infected RBC (PfRBC) were washed twice in RPMI, cryopreserved in glycerol-containing freeze medium, and used upon thawing in stimulation assays. Mock-cultured uninfected erythrocytes (uRBC) were obtained similarly and served as the control.

*P. falciparum* lysate for enzyme-linked immunosorbent assay (ELISA) was prepared by extracting purified schizonts/mature trophozoites with 1% sodium desoxycholate and 2.5 μL phenylmethanesulfonyl fluoride protease inhibitor for 15 min at room temperature (RT).

Recombinant and synthetic proteins. Recombinant proteins of circumsporozoite protein (CSP) and liver-stage antigen 1 (LSA-1) were used to probe humoral responses toward preerythrocytic stages, while crude *P. falciparum* lysates were used to assess antibody reactivity toward blood stages. Apical membrane protein 1 (AMA-1) and exported protein 1 (EXP-1) are expressed in both preerythrocytic and asexual stages.

Full-length *P. falciparum* NF54 CSP with repeats was produced in Escherichia coli by Gennova Biopharmaceuticals Ltd., Pune, India. A recombinant LSA-1 construct, LSA-NRC, was expressed in *E. coli*, incorporating the N- and C-terminal regions of the protein and two of the centrally placed 17-amino-acid repeats for the 3D7 LSA-1 sequence (PlasmoDB-PF3D7_1036400) (28). Both the N- and C-terminal regions as well as the repeats are highly conserved between NF54 and 3D7. The major difference is the greater number of repeats, which are the primary target of anti-LSA-1 antibodies (29), in the NF54 sequence than in the 3D7 sequence (30). Amino acids 25 to 545 of codon-optimized AMA-1 of the *P. falciparum* FVO strain were expressed in the methylotropic yeast *Pichia pastoris* (31, 32). A peptide covering the C-terminal amino acids 73 to 162 of the integral parasitophorous vacuolar membrane protein export protein 1 (Swiss-Prot Database primary accession number P04926) was chemically synthesized using solid-phase 9-fluorenylmethoxy carbonyl (Fmoc) chemistry and differs from the 3D7 sequence only by a single amino acid in position 160 (33).

ELISA to assess antibody reactivity. Ninety-six-well Polystyrene flat-bottom plates (Nunc Maxisorp; Thermo Scientific) were coated with 2 μg/mL of CSP, EXP-1, and AMA-1, 0.25 μg/mL of LSA-1, or *P. falciparum* lysate at the equivalent of 20,000 PFRCW/well in phosphate-buffered saline (PBS) and incubated overnight at 4°C. Plates were blocked with 5% milk in PBS. All of the following washing steps were carried out with PBS-0.05% Tween (PBST). Using 1% milk in PBST, plasma or serum samples were serially diluted in duplicate starting at 1:50 to 1:800 for protein antigen and 1:250 to 1:4,000 for *P. falciparum* lysate and incubated for 3 h at room temperature. Bound IgG was detected using horseradish peroxidase (HRP)-conjugated anti-human IgG (Thermo Scientific; diluted 1:60,000 in sample buffer). Plates were developed using tetramethylbenzidine (TMB) peroxidase substrate (tebu-bio). The reaction was stopped using an equal volume of 0.2 M H₂SO₄, and absorbance was measured with a spectrophotometer plate reader at 450 nm (Anthos 2001 ELISA plate reader).
A serial dilution of a pool of sera from 100 hyperimmune Tanzanian (HIT) (20) individuals living in an area where malaria is highly endemic was used as a reference standard and was included on each plate. The reactivity for each antigen in undiluted HIT serum was defined as 100 arbitrary units (AUs). Optical density (OD) values were converted into AUs by using the four-parameter logistic curve fit using the Auditable Data Analysis and Management System for ELISA (ADAMSEL-v1.1; http://www.malariairesearch.eu/content/software).

For each antigen, at least three time points of an individual volunteer were assayed on the same plate. To determine whether Tanzanians had a positive *P. falciparum* serology (by recognition of *P. falciparum* lysate), the mean (+2 standard deviations [SD]) baseline antibody titer against *P. falciparum* lysate of the Dutch volunteers was used as the cutoff for positivity.

In *vitro* PBMC stimulation assay to assess cellular responses. Venous whole blood was collected into citrated Vacutainer CPT cell preparation tubes (Becton Dickinson). PBMCs were obtained by density gradient centrifugation, washed three times in cold PBS, counted, frozen at 10^7 cells/ml in fetal calf serum (FCS) with 10% dimethyl sulfoxide, and stored in vapor-phase nitrogen. After being thawed, PBMCs were counted and cultured at a concentration of 500,000 cells/well in a 96-well round-bottom plate and stimulated in duplicate at a ratio of 1:2 with 10^9 *P. falciparum* NF54-infected RBC or uRBC for either 24 h or 6 days in a total volume of 200 μl.

Flow cytometry. Cells were stained and analyzed by flow cytometry either directly *ex vivo* or after 24 h or 6 days of *in vitro* stimulation. Cells were stained first for viability with LIVE/DEAD fixable Aqua dead cell stain (Invitrogen) or fixable viability dye eFluor 780 (eBioscience) and later with three different staining panels for surface markers: for the 24-h stain, CD3 PerCP (UCH1; BioLegend), CD56-phycoerythrin (PE) (HCD56; Biolegend), anti-T-cell receptor (TCR) Pan γ/δ-PE (IMMU510; Beckman Coulter), CD4 Pacific Blue (OKT4; Beckman Coulter), CD8allophycocyanin (APC)-H7 (SK1; BD Pharmingen), CD45RO energy-coupled dye (ECD) (UCH1; Beckman Coulter), and CD46 ECD (DREG56; eBioscience); for the ex vivo stain, the only changes from the previous stain were CD3 V500 (clone SP342; BD Horizon) and CD8 PerCP (RPA-T8; BioLegend); and for the third-panel 6-day stain, CD3 PerCP (RP A-T8; BioLegend) and CD8 PeCy7 (OKT3; BioLegend) and CD8 PerCP (RP A-T8; BioLegend). For intracellular staining, cells were incubated with different monoclonal antibodies (MAbs) depending on the staining panels. After 30 min of incubation at RT, cells were washed and permeabilized with Fix/Perm fix/perm buffer (eBioscience) for 30 min on ice and stained in permeabilization buffer (eBioscience) with IFN-γ fluorescein isothiocyanate (FITC) (4S.B3; eBioscience; 24-h stain) and Fix/Perm eF660 (PCH101; bioLegend; ex vivo stain) or Ki67 FITC (B56; BD Pharmingen) and Fix/Perm eF660 (PCH101; eBioscience; 6-day stain). Cells were collected on a CyAn ADP 9-color flow cytometer (Dako/Beckman Coulter) and analyzed using FlowJo software (Tree Star, Inc.) version 9.6. All assays were conducted with the same batches of PRBC and uRBC, with all time points of one volunteer assayed in one experiment to prevent interassay variations. Natural killer T cells (NKT) and gamma delta T cells (γδT) were analyzed in the same gate and henceforth are referred to as NKT-γδT cells.

Statistical analysis. Statistical analysis was performed in GraphPad Prism 5. Differences within the cohorts and between time points were analyzed per volunteer by a Wilcoxon matched-pairs signed-rank test and those between groups were analyzed by a Mann-Whitney U test. The relationship between baseline antibody titers and the increase in antibody titers was analyzed by Spearman correlation, and P values of <0.05 were considered statistically significant. Cellular responses were corrected for the background by subtracting responses to uRBC from responses to PRBC for each sample; resulting negative values were set to zero.

RESULTS

Tanzanian volunteers have higher baseline antibody titers than Dutch subjects. Pre-CHMI antibody titers were significantly higher in Tanzanian than in the malaria-naïve Dutch volunteers for crude *P. falciparum* lysate (*P* < 0.03), with 12/21 Tanzanians having titers higher than the mean (+2 SD) titers of Dutch volunteers. This was also true for pre-CHMI antibodies to the individual parasite antigens AMA-1 (*P* < 0.015; 13/21) and CSP (*P* < 0.04; 15/21), and the same trend was found for EXP-1 (*P* < 0.06; 8/21) (Fig. 1A). Elevated LSA-1 antibody titers were found in 5/21 Tanzanians, but there was no significant difference between Dutch and Tanzanian at the group level (*P* < 0.16). Within the Tanzania cohort, there was a wide range of pre-CHMI antibody responses, with some volunteers showing only low responses, comparable to those of the Dutch cohort. To address whether there was a general division into high and low responders to malaria antigens, we stratified Tanzanian individuals based on their reactivity to *P. falciparum* lysate (containing a large number of late-liver- and blood-stage antigens) (Fig. 1B). Compared to their *P. falciparum* lysate-seronegative counterparts (*n* = 9), seropositive Tanzanians (*n* = 12) had significantly higher antibody titers against the cross-stage antigens AMA-1 (*P* = 0.005; 7.6-fold higher median titer) and EXP-1 (*P* = 0.04; 5.4-fold higher). The same trend was found for the sporozoite antigen CSP (*P* = 0.09; 2.4-fold higher) and the liver-stage antigen LSA-1 (*P* = 0.06; 1.7-fold) (Fig. 1C).

*P. falciparum* lysate seropositivity prior to CHMI is associated with reduced initial blood-stage parasitemia. We next assessed whether preexisting humoral responses might be associated with the control of parasites in Tanzanian volunteers. In line with stronger humoral responses in the Tanzanian cohort than in the Dutch cohort at baseline, Tanzanian volunteers became qPCR positive significantly later than the Dutch volunteers (Fig. 2A), with a median prepatent period of 11.0 days (interquartile range [IQR], 11.0 to 13.5) in Tanzanians and 10.0 days (9.5 to 11.0) in Dutch volunteers (*P* = 0.009). Similarly, prepatency by TS was also longer in Tanzanians (median [IQR], 13.7 days [12.75 to 16.7]) than in the Dutch (12.6 days [12.3 to 14]) (*P* = 0.035). The time between detection by qPCR and by TS was comparable for both cohorts (median [IQR], 2.6 days [2.2 to 3.1]) in Tanzanians, 3.0 days [2.0 to 3.15] (*P* = 0.88), but Dutch volunteers had a significantly higher peak parasite density (median number of parasites/milliliter [IQR], 12,000 [6,800 to 15,000]; Dutch, 74,000 [26,000 to 190,000]; *P* = 0.02), possibly due to slight differences in the thick smear protocol between the two sites. Within the Tanzania cohort, there was no significant difference in time to qPCR-detectable parasitemia between volunteers who were either *P. falciparum* lysate seropositive or seronegative at baseline (*P* = 0.16) (Fig. 2B), nor was there a difference in prepatency by TS (*P* = 0.41) or time between detection by qPCR and TS (*P* = 0.15). However, seropositive Tanzanian volunteers had a significantly lower parasite load at the time of first qPCR-detectable parasitemia than their seronegative counterparts (*P* = 0.033) (Fig. 2C). This difference remained evident, but became smaller, by the time the first peak in parasite load was reached (*P* = 0.05; Fig. 2D). Across all Tanzanian volunteers, pre-CHMI antibody titers for CSP (Pearson *r* = 0.45, *P* = 0.04), but no other antigens, correlated significantly with prepatency by qPCR (see Fig. S1 in the supplemental material).

*P. falciparum*-specific antibody responses are more efficiently increased in Tanzanians than in Dutch volunteers after CHMI. Post-CHMI, antibody responses increased significantly in the Tanzanian volunteers for *P. falciparum* lysate (*P* < 0.001; 15/21 with a >3-fold increase in titers), AMA-1 (*P* = 0.002; 6/21), EXP-1 (*P* < 0.0001; 14/21), LSA-1 (*P* = 0.001; 5/21), and CSP
In contrast, the Dutch volunteers showed significant increased titers only against EXP-1 \((P = 0.004; 7/9)\) and CSP \((P = 0.008; 3/9)\), while responses to LSA-1 and AMA-1 remained low and unaltered (Fig. 3B). Compared to the Dutch, Tanzanians showed a trend for stronger induction or boosting of responses based on the overall fold increase in titers to \(P. falciparum\) lysate, AMA-1, and LSA-1 (Fig. 3C) and significantly higher absolute increases in titers for these antigens (Fig. 3D). Volunteers in both cohorts were subjected to CHMI with either 10,000 or 25,000 PfSPZs. However, the only significant difference in antibody responses between the two dose groups was a slightly higher response in the 25,000 than in the 10,000 dose group for \(P. falciparum\) lysate in Dutch volunteers \((P = 0.04)\) and a similar trend for the Tanzanians for CSP \((P = 0.07)\) (see Fig. S2 in the supplemental material). Post-CHMI, \(P. falciparum\) lysate-seronegative Tanzanians had a significantly stronger fold increase in antibody titers against AMA-1 \((P = 0.02)\) and EXP-1 \((P = 0.04)\) than seropositive individuals, with a similar trend for \(P. falciparum\) lysate \((P = 0.082)\) and CSP \((P = 0.095)\), but no difference in LSA-1 responses \((P = 0.80)\) (Fig. 3E). For the entire cohort, the fold increase of \(P. falciparum\) lysate and AMA-1 responses upon CHMI correlated negatively with the baseline response. The absolute increase in titers, however, was not different for any of the antigens between the two dose groups.
groups (Fig. 3F). Notably, *P. falciparum* lysate-seronegative Tanzanians thereby also showed a greater absolute increase in antibody titers than malaria-naive Dutch volunteers.

Dutch but not Tanzanian volunteers show cellular recall responses induced by CHMI. To analyze the acquisition of cellular responses after CHMI, we investigated *in vitro* IFN-γ responses upon incubation with PfRBC for 24 h (Fig. 4A and B). At baseline, *P. falciparum*-specific IFN-γ responses were comparable between Dutch and Tanzanians for all cell subsets except for NKT-γδT cells, which showed slightly higher responses in the Dutch (P = ...
Dutch but not Tanzanian volunteers show increased *P. falciparum*-specific *in vitro* IFN-γ production after CHMI. PBMCs collected pre- and post-CHMI from Dutch (D; circles; \(n = 9\); post = 35 days after CHMI) and Tanzanian (T; squares; \(n = 21\); post = 28 days after CHMI) volunteers were stimulated with PFRC for 24 h. (A) After stimulation, cells were stained for surface expression of CD3, CD4, γδTCR, CD8, and CD56 to gate lymphocyte subsets. NKT and γδT were gated as a combined population. (B) Intracellular IFN-γ is shown for total lymphocytes after 24 h of uRBC or PfRBC stimulation. Graphs show the proportions of cells with *P. falciparum*-specific IFN-γ production, comparing Dutch and Tanzanian volunteers pre-CHMI (C) and post-CHMI (D), and comparing pre- and post-CHMI among Dutch (E, F) and Tanzanian (G, H) volunteers.

**FIG 4** Dutch but not Tanzanian volunteers show increased *P. falciparum*-specific *in vitro* IFN-γ production after CHMI. PBMCs collected pre- and post-CHMI from Dutch (D; circles; \(n = 9\); post = 35 days after CHMI) and Tanzanian (T; squares; \(n = 21\); post = 28 days after CHMI) volunteers were stimulated with PFRC for 24 h. (A) After stimulation, cells were stained for surface expression of CD3, CD4, γδTCR, CD8, and CD56 to gate lymphocyte subsets. NKT and γδT were gated as a combined population. (B) Intracellular IFN-γ is shown for total lymphocytes after 24 h of uRBC or PfRBC stimulation. Graphs show the proportions of cells with *P. falciparum*-specific IFN-γ production, comparing Dutch and Tanzanian volunteers pre-CHMI (C) and post-CHMI (D), and comparing pre- and post-CHMI among Dutch (E, F) and Tanzanian (G, H) volunteers.
FIG 5  *P. falciparum*-specific *in vitro* IFN-γ production by innate lymphocytes from Tanzanian volunteers is dependent on baseline serological status. PBMCs collected from Tanzanian volunteers who either had a positive *P. falciparum* serology (Sero+; n = 12; black squares) or negative *P. falciparum* serology (Sero−; n = 9; white squares) serology prior to challenge (baseline) were stimulated with PfRBC for 24 h and stained for intracellular IFN-γ. Panels show IFN-γ production by lymphocyte subsets: (A) CD4+ T cells; (B) CD8+ T cells; (C) NKT-γδT cells; (D) CD56dim; (E) CD56bright NK cells. Data are shown as median ± IQR of responses corrected for the background by subtracting responses to uRBC. Differences in responses between the seropositive and seronegative groups were analyzed by a Mann-Whitney U test. Responses corrected for the background by subtracting responses to uRBC. Responses pre-CHMI and post-CHMI were compared using a Wilcoxon matched-pairs signed-rank test.

Reduced innate IFN-γ responses in Tanzanian volunteers are associated with preexisting humoral immunity and thus potential preexposure. Finally, we analyzed whether the degree of preexposure reflected by differences in malaria-specific humoral immunity might affect cellular recall responses to PfRBC. Cells from *P. falciparum* lysate-seronegative Tanzanian volunteers had significantly higher responses to PfRBC (pre-CHMI) than those from seropositive Tanzanian volunteers (NKT-γδT, P = 0.05; CD56dim, P = 0.01; CD56bright NK, P = 0.04) and were of a magnitude comparable to those observed in the Dutch volunteers (Fig. 5). CD4+ and CD8+ T cells showed a similar pattern, although the difference between seropositive and seronegative Tanzanians did not reach statistical significance (Fig. 5A and B). Post-CHMI, these differences remained, and there was no increase in these responses in either of the two groups.

**DISCUSSION**

In the present study, we performed a side-by-side comparison of antimalarial immune responses initiated or recalled by CHMI in two cohorts of young adults, from The Netherlands and Tanzania, with different malaria exposure histories and genetic backgrounds. Recruitment of Tanzanian volunteers took place in Dar es Salaam, an urban area where malaria is hypoenemic. Inclusion criteria into this CHMI trial were tailored to ensure minimal recent exposure to *P. falciparum*: Tanzanian volunteers had not experienced a clinical episode of malaria for 5 years, as self-reported, and were confirmed free of parasites by qPCR before CHMI took place. Nevertheless, more than 50% of the 21 Tanzanian volunteers had a positive *P. falciparum* lysate serology before CHMI.
based on *P. falciparum* lysate ELISA, which is a standard exclusion criterion in Dutch CHMI trials. In line with this, increased baseline antibody titers for the *P. falciparum* antigens CSP, LSA-1, EXP-1, and AMA-1 were found in the Tanzania cohort and particularly in those with positive serology for *P. falciparum* lysate. This clearly indicates previous exposure to the malaria parasite in this cohort. Asymptomatic infections, which can often occur in people living in areas with low malarial endemicity (34), in the 5 years of no self-reported clinical malaria preceding CHMI might have led to a maintenance of higher antibody responses. As might be expected, preexisting antibodies to *P. falciparum* antigens appeared to have an effect on the outcome of CHMI. Tanzanians had a significantly longer prepatency based on qPCR detection than the previously malaria-naive Dutch. Furthermore, *P. falciparum* lysate-seropositive Tanzanians had a lower parasite load at the time of first detection by qPCR and at the time of the first peak of parasite load than seronegative Tanzanians. The first peak of blood-stage parasitemia can be used as a proxy for parasite liver load (16, 35). Our results might therefore indicate the emergence of fewer parasites from the liver and hence better control of either initiation or progression of liver-stage infection in preexposed individuals within the Tanzanian cohort and in Tanzanians than in the Dutch cohort. In line with such an effect of preexisting antispore parasite immunity would be the observation that those Tanzanian volunteers with a longer prepatency by qPCR also had higher baseline antibody titers against the spore antigen CSP. However, the first detection by qPCR in both the Dutch and Tanzanian after intradermal PISPZ injection was uncharacteristically late compared to that for infection by mosquito bite routinely conducted in The Netherlands and elsewhere (11, 16, 18, 19, 23, 24, 35). This is likely due to less efficient liver-stage infection by this route and hence a low initial blood-stage load that reaches the qPCR detection limit only later. A lower first detectable parasitemia in seropositive Tanzanians than in seronegative Tanzanians might therefore additionally be attributed to the control of blood-stage replication prior to qPCR detection. Antibodies directed against AMA-1, for instance, are known to interfere with blood-stage multiplication (36) but can also confer protection against liver-stage infection (37). Since recognition of both cross-stage and liver-stage antigens was stronger in the Tanzanian cohort than in the Dutch, and particularly in the seropositive individuals, both possibilities remain open. Our data, however, support antibody control of blood-stage replication only during the initial phase of sub-qPCR-detectable parasitemia: while parasite multiplication based on PCR data could not be directly compared due to the high variability of the amplification dynamics (24), there was no difference between prepatency by TS and qPCR in the two Tanzanian groups.

Upon CHMI, Dutch volunteers showed a slight but significant induction of humoral responses against CSP, *P. falciparum* lysate, and EXP-1, while Tanzanians boosted responses to all antigens examined. Reactivity to the CSP spore antigen is expected after PISPZ inoculation and consistent with previous findings (38, 39). Increased antibody responses against *P. falciparum* lysate and EXP-1 likely reflect cross-stage reactivity between late-liver-stage and blood-stage merozoites, while exposure to developing liver stages (LSA-1) in naive volunteers appears insufficient to induce a detectable antibody response. Similarly, limited exposure to blood-stage-expressed AMA-1, due to early curative treatment, appears to prevent induction of detectable titers in naive volunteers, which is consistent with results even after multiple CHMIs (39). Consistent with preexposure, Tanzanians showed on the group level a greater increase in titers for *P. falciparum* lysate, AMA-1, and LSA-1 than the previously malaria-naive Dutch. Within the Tanzanian cohort, *P. falciparum* lysate-seronegative Tanzanians showed a similar absolute and accordingly much greater fold increase in antibody titers than their seropositive counterparts. At baseline, these volunteers had significantly lower responses to most parasite antigens than their seropositive counterparts and largely resembled the malaria-naive Dutch cohort. The fact that this group showed a greater increase in antibody titers than the Dutch strongly suggests that despite largely negative *P. falciparum* serology, these individuals have a stable *P. falciparum*-specific memory B-cell repertoire (40, 41). Given the same increase in absolute antibody titers, their memory B-cell repertoire appears to be of a magnitude similar to that of the *P. falciparum* lysate-seropositive Tanzanians, despite lower circulating plasma antibody levels.

Of note, humoral responses were assessed using a number of recombinant or synthetic proteins, which are not fully identical to the sequences of these proteins expressed by the NF54 strain used in both CHMI trials. While most antigens used in this study were of the 3D7 sequence and thus closely resemble the NF54 sequence, AMA-1 responses were assessed using the FVO strain sequence. AMA-1 is known for its extensive antigenic polymorphism and to cause strain-specific immunity (42, 43). Nevertheless, there is a significant antigenic overlap between AMA-1 alleles allowing for cross-reactivity across different strains, both in terms of functional activity and recognition, which affects mainly the magnitude of the response (42, 44–46). Based on these data, we consider it unlikely that assessment of AMA-1 responses using the NF54 or 3D7 sequence would have yielded different qualitative results. However, absolute titers would likely have been higher when using the AMA-1 sequence homologous to the CHMI strain.

Another potential confounder is the fact that the *P. falciparum* strains that Tanzanian volunteers were naturally exposed to prior to CHMI with *P. falciparum* NF54 are unknown. As any study examining preexposed individuals, analysis of antigen-specific responses against polymorphic antigens has therefore the additional limitation that it is difficult to match this unknown exposure history. This has to especially be taken into account when investigating CHMI-induced boosting of potential preexisting responses in this cohort, which might be masked by using antigens of different strain origins. However, despite the fact that Tanzanians likely experienced exposure to a variety of *P. falciparum* strains prior to CHMI, there was (i) a clear division into seropositive and seronegative individuals not just by total *P. falciparum* NF54 lysate but also by all individual antigens analyzed and (ii) a clearly stronger increase in antibody titers in Tanzanians than in malaria-naive Dutch volunteers to several antigens, including AMA-1. We cannot exclude, however, that this might have even been more pronounced when using antigens of different strain origins for analysis.

Although the Tanzanian volunteers in the present study showed evidence of humoral immune memory, parasite-specific IFN-γ production by adaptive T-cell subsets was not higher than in malaria-naive Dutch volunteers at baseline and remained unchanged after CHMI. In contrast, previously naive Dutch volunteers showed a significant increase in IFN-γ production by CD4 and CD8 T-cell subsets after a primary infection, consistent with
what has been shown previously (47, 48). The lack of increased proliferative and Th1 responses 1 month after CHMI in Tanzanian volunteers could be partially due to immunosuppression following exposure to blood-stage parasites during CHMI. Such T-cell immunosuppression is well described for malaria (49–58) and, although usually resolved within 2 weeks (52, 53), can persist for more than 4 weeks (50). That Dutch volunteers are not equally affected by this might be due to the fact that such immunosuppressive effects appear to be more pronounced in immune than in nonimmune donors, as shown elsewhere (59). T regulatory cells (Tregs) are one potential mediator of suppressed IFN-γ production by adaptive cells. Increased Treg numbers during or after malaria are a well-reported phenomenon (60), and malaria parasites can enhance the suppressive activity of Tregs (61). While Dutch and Tanzanian volunteers had similar Treg proportions, we cannot exclude that Tregs in Tanzanian volunteers might be functionally more active, potentially due to past priming in malaria infections. That this apparent lack of a Th1 immune response in the Tanzanian cohort is malaria specific is supported by the fact Dutch and Tanzanian volunteers showed similar Th1 responses to mitogen stimulation both pre- and post-CHMI. Nevertheless, an additional influence of genetic background, which may explain differential P. falciparum-specific responses described in settings where malaria is endemic, cannot be excluded (62, 63).

NK cells are rapidly activated by malaria parasites, contribute to the early IFN-γ response during blood-stage infection (64), and can eliminate infected erythrocytes in vivo in a contact-dependent manner (65). Importantly, there is a functional dichotomy: the rarer CD56bright cells are more prominent in lymphatic tissues and are superior cytokine producers, while the CD56dim subset harbors a stronger cytotoxic potential (66–68). However, NK cells have usually been examined as one population, and the exact contributions of CD56dim and CD56bright NK cell subsets to malaria immunity thus remain to be established. An in vitro study on PBMCs from malaria-naive donors found greater IFN-γ production by CD56bright than by CD56dim NK cells only in response to cytokines but not upon PfRBC stimulation (69). However, consistent with their generally reported greater cytotoxic potential, only CD56dim cells showed degranulation upon PfRBC stimulation (69). Our findings that CD56bright NK cells show a greater IFN-γ response than CD56dim NK cells to PfRBC both before and after a primary malaria infection, as well as a memory-like effect of this response, are in line with findings from a previous CHMI trial (70). Tanzanian volunteers showed the same functional difference between the two NK cell subsets but no memory effect in either subset after CHMI. It was previously shown that depletion of αβ T cells abrogates memory-like IFN-γ responses of innate cells otherwise observed after CHMI (47, 70). Therefore, the absence of increased PfRBC-specific αβ T-cell responses post-CHMI in Tanzania volunteers might be one reason why P. falciparum-specific IFN-γ production by NK cells and other innate lymphocytes (NKT and γδ T cells) was also not increased post-CHMI. The fact that P. falciparum lysate-seronegative Tanzanians had higher innate IFN-γ responses than did seropositive Tanzanians already at baseline is a further indication that reduced Th1 responses are likely linked to the degree of previous malaria exposure. Of note, the proportion of CD56bright cells remained unaltered after CHMI, while the CD56dim subset had a smaller contribution to the PBMC compartment post-CHMI in both cohorts. It remains to be established whether this means that, in contrast to memory-like IFN-γ production, other NK cell functions, such as migration out of the circulation and engagement in antimalaria immune responses at other sites, such as the spleen, are unaffected and fully functional in preexposed individuals.

Within the Tanzanian cohort, there was no association of pre-existing P. falciparum-specific IFN-γ responses by T-cell subsets or innate lymphocytes with the parasitological outcome of CHMI, i.e., prepatency or parasite load at first detection by qPCR. If at all, those with higher IFN-γ responses to blood-stage PfRBC had a shorter prepatency. This does not, however, exclude that cellular responses play a role in the prolonged prepatency of Tanzanian volunteers and specifically those with positive P. falciparum serology. One possible reason for the lack of such an association is that PfRBC were chosen as a stimulus for P. falciparum-specific responses. This was done due to the relatively large antigenic overlap between blood-stage and (late) liver-stage parasites (71, 72). However, responses to sporozoite and early-liver-stage antigens, which may be more relevant when assessing responses responsible for reducing the parasite load by targeting the earlier stages of infection, are likely to be missed using PfRBC as a stimulus. Moreover, our analysis was restricted to P. falciparum-specific IFN-γ production, and it is likely that other responses, for instance, degranulation as a proxy for cytotoxicity, may be more relevant readouts (71). Finally, the only accessible compartment for analysis of cellular responses in these human trials was peripheral blood. P. falciparum-specific responses, and particularly those responsible for reducing liver infection, might, however, be enriched or primarily located in other sites, for instance, in tissue-resident memory cells in the liver (73, 74). This might be even more pronounced in preexposed individuals, where such a tissue-resident memory population might have already been established.

Noteworthy, the differential immune responses described herein may explain why Tanzanian volunteers reported fewer clinical symptoms, such as fever, than their Dutch counterparts during CHMI after PfSPZ injection (24). On the one hand, pre-existing antibody responses may reduce the initial parasite load and mediate antisede immunity. Additionally, the relatively lower P. falciparum-specific cellular Th1 responses observed in the Tanzanian cohort than in the Dutch cohort might also be beneficial. Dutch volunteers preexposed to infected mosquito bites under chloroquine prophylaxis exhibited stronger IFN-γ production and earlier clinical symptoms when reexposed to blood-stage parasites than malaria-naive volunteers during their first infection (15). Thus, a shift away from Th1 responses in preexposed volunteers may make them less vulnerable to fever and other inflammation-induced symptoms.

In conclusion, our data show that previous malaria exposure is associated with some degree of parasite control during liver-stage or early-blood-stage infection after CHMI, humoral immune memory, and reduced antiparasite Th1 responses in the circulating lymphocyte compartment. Positive P. falciparum lysate serology can be used to identify individuals with better parasite control but weaker peripheral blood Th1 responses, which may help to stratify volunteers in future CHMI trials in areas where malaria is endemic. However, assessment of memory B-cell responses might be explored as a potentially better tool than serology to define preexposure per se. Important questions to be addressed in future studies include (i) which readouts other than Th1 responses should be used to determine immunization-induced cellular immunity and (ii) how differences in preexisting malaria-specific
immune responses affect the outcome of whole parasite immunization and vaccination approaches in areas where malaria is endemic.

ACKNOWLEDGMENTS

We thank all the trial volunteers and the staff from the Radboud University Medical Center, the Ifakara Health Institute/Bagamoyo Research and Training Centre, Sanaria Inc., and the Swiss Tropical and Public Health Institute, all of whom made this study possible. We thank S. Singh (Genova Biopharmaceuticals), D. Lanar, and G. Corradin for providing recombinant and synthetic CSP, LSA-1, and EXP-1 proteins, respectively. We thank M. van de Veget-Bolmer, R. Siebelt-Stoter, and W. Grau


5. RTS, Clinical Trials Partnership, Agnandji ST, Lell B, Fernandez JF, Aboso

obero et al.

2194

Infection and Immunity

May 2015

Volume 83

Number 5


Downloaded from http://iai.asm.org/


